Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adults aged 18-40 years and children aged 1 -17 years who the investigator believes will comply with the requirements of the protocol (i.e. available for follow-up visits and specimen collection).~2. For females of reproductive age, they must not be pregnant (as determined by verbal screening).~3. Written informed consent obtained from the subjects or their parents/guardians, and written assent for children aged 12 - 17 years.~4. Healthy subjects as determined by: Medical history, Physical examination, Clinical judgment of the investigator~Exclusion Criteria:~1. Ongoing serious chronic disease~2. Immunocompromising condition or therapy~3. Diarrhea (3 or more loose/more watery stools within a 24-hour period) 6 weeks prior to enrollment~4. One or two episodes of diarrhea lasting for more than 2 weeks in the past 6 months~5. One or two episodes of abdominal pain lasting for more than 2 weeks in the past 6 months~6. Intake of any anti-diarrhea medicine in the past week~7. Abdominal pain or cramps, loss of appetite, nausea, general ill-feeling or vomiting in the past 24 hours~8. Acute disease one week prior to enrollment, with or without fever. Temperature ≥38ºC (oral) or axillary temperature ≥ 37.5ºC warrants deferral of the vaccination pending recovery of the subject~9. Receipt of antibiotics in past 14 days~10. Receipt of live or killed enteric vaccine in past 4 weeks~11. Receipt of killed oral cholera vaccine

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Vaccine (Type: EXPERIMENTAL): killed bivalent (O1 and O139)whole cell oral cholera vaccine(Shanchol™)

Based on this trial design, predict the completion outcome and termination type (if applicable).